Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 40

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 40
---
 to our Report on Form 6-K dated December 21, 2023. Unless otherwise
stated, references to warrants in this subsection include the Series E Warrants, the December 2023 Private Placement Pre-Funded Warrants,
and the December 2023 Underwriter Warrants.

Exercisability. The warrants
became exercisable on December 21, 2023. The Series E Warrants and December 2023 Underwriter Warrants expire five years and three years,
respectively from the initial exercise date. The December 2023 Private Placement Pre-Funded Warrants are exercisable at any time and
do not expire. The holder shall deliver the aggregate exercise price for the Depositary Shares specified in the exercise notice within
two trading days following the date of exercise (subject to the ‘cashless exercise’ arrangements described below).

Cashless Exercise. If,
at the time a holder exercises its Series E Warrants, a registration statement registering the issuance of the securities underlying
the Series E Warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities
Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us
upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in
whole or in part) the net number of Depositary Shares determined according to a formula set forth in the Series E Warrants.

At the time a holder exercises its
December 2023 Private Placement Pre-Funded Warrants, in lieu of making the cash payment otherwise contemplated to be made to us upon
such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole
or in part) the net number of Depositary Shares determined according to a formula set forth in the December 2023 Private Placement Pre-Funded
Warrants.

Exercise Price.The exercise
price of each Series E Warrant, December 2023 Underwriter Warrant and December 2023 Private Placement Pre-Funded Warrant is $550.00,
$625.00 and $0.025 per Depositary Share.

Beneficial Ownership Limitation. A
holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect to such exercise, such holder,
together with such holder’s affiliates, and any persons acting as a group together with such holder or any such affiliate